KRAS and skin neoplasm: The KRAS G60R mutation was detected in In‐N (VAF 36.3%) and skin tumor (VAF 23.0%), while the TERT‐p C228T mutation was detected in In‐N (VAF 35.5%) and skin tumor (VAF 25.9%) (Table 1).